NEVVI Medicare utilization intelligence

← back

Provider profile

ZHU, MOJUN M.D.

Medical Oncology · NPI 1376923581 · SCOTTSDALE, AZ

2
Groups
38
Codes · 2024
39,574
Disclosed services

ZHU, MOJUN is a Medical Oncology in SCOTTSDALE, AZ, a member of 2 medical groups, who billed 38 distinct codes to Medicare Part B in 2024.

Groups: MAYO CLINIC (ROCHESTER, MN) · MAYO CLINIC ARIZONA (PHOENIX, AZ) — member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

39,574
disclosed services
38
codes billed to Medicare Part B
Prior year · CY2023 45,745 disclosed services

This provider's disclosed Medicare payments across all codes were premium in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg premiumpremium premiumpremium
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj premiumpremium premiumpremium
J1453 Injection, fosaprepitant, 1 mg premiumpremium premiumpremium
J9267 Injection, paclitaxel, 1 mg premiumpremium premiumpremium
J9263 Injection, oxaliplatin, 0.5 mg premiumpremium premiumpremium
J1100 Injection, dexamethasone sodium phosphate, 1 mg premiumpremium premiumpremium
J9041 Injection, bortezomib, 0.1 mg premiumpremium premiumpremium
J2469 Injection, palonosetron hcl, 25 mcg premiumpremium premiumpremium
J0461 Injection, atropine sulfate, 0.01 mg premiumpremium premiumpremium
J2405 Injection, ondansetron hydrochloride, per 1 mg premiumpremium premiumpremium
96375 Injection of additional new drug or substance into vein premiumpremium premiumpremium
96413 Administration of chemotherapy into vein, 1 hour or less premiumpremium premiumpremium
J9190 Injection, fluorouracil, 500 mg premiumpremium premiumpremium
J9045 Injection, carboplatin, 50 mg premiumpremium premiumpremium
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more premiumpremium premiumpremium
J9206 Injection, irinotecan, 20 mg premiumpremium premiumpremium
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg premiumpremium premiumpremium
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle premiumpremium premiumpremium
96415 Administration of chemotherapy into vein, each additional hour premiumpremium premiumpremium
96417 Administration of additional new drug or substance into vein, 1 hour or less premiumpremium premiumpremium
J9217 Leuprolide acetate (for depot suspension), 7.5 mg premiumpremium premiumpremium
J1200 Injection, diphenhydramine hcl, up to 50 mg premiumpremium premiumpremium
J3490 Unclassified drugs premiumpremium premiumpremium
J0640 Injection, leucovorin calcium, per 50 mg premiumpremium premiumpremium
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less premiumpremium premiumpremium
96372 Injection of drug or substance under skin or into muscle premiumpremium premiumpremium
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle premiumpremium premiumpremium
J7030 Infusion, normal saline solution , 1000 cc premiumpremium premiumpremium
96361 Infusion into a vein for hydration, each additional hour premiumpremium premiumpremium
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more premiumpremium premiumpremium
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l premiumpremium premiumpremium
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's premiumpremium premiumpremium
96411 Administration of additional new drug or substance into vein using push technique premiumpremium premiumpremium
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion premiumpremium premiumpremium
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more premiumpremium premiumpremium
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) premiumpremium premiumpremium
36591 Collection of blood sample from implanted device premiumpremium premiumpremium
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less premiumpremium premiumpremium

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.